ORBERA? INTRAGASTRIC BALLOON SYSTEM B-4800

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2020-02-24 for ORBERA? INTRAGASTRIC BALLOON SYSTEM B-4800 manufactured by Apollo Endosurgery, Inc..

Event Text Entries

[182191148] Initial medwatch sent to the fda. A review of the device labeling notes the following: the current orbera? Intragastric balloon system directions for use (dfu) addresses the known and anticipated potential events of "pain", "ischemia", "nausea", "vomiting", "early removal", "aspiration" and "necrosis" as follows: precautions: antiemetics, antispasmodic, and anticholinergic drugs may be prescribed to lessen the early placement symptoms such as nausea, vomiting, and abdominal pain. Patients will need to immediately contact their physician for any severe or unusual symptoms. Placement of the balloon within the stomach produces an expected and predictable reaction characterized most commonly by a feeling of heaviness in the abdomen, nausea and vomiting, gastroesophageal reflux, belching, esophagitis, heartburn, diarrhea and, at times, abdominal, back or epigastric pain and cramping. Food digestion may be slowed during this adjustment period. These symptoms can be treated with antiemetic, antispasmodic, and anticholinergic medications. Typically the stomach acclimates to the presence of the device within the first 2 weeks. In order to prevent or ameliorate the symptoms most frequently experienced during the adjustment period, it is recommended that the physician use proton pump inhibitors (ppis), antiemetics, antispasmodics, and anticholinergic medications prophylactically (before orbera? Placement). Patients should be advised to immediately contact their physician for any unusually severe or worsening symptoms. The physiological response of the patient to the presence of orbera? May vary depending upon the patient's general condition and the level and type of activity. The types and frequency of administration of drugs or diet supplements and the overall diet of the patient may also affect the response. Each patient must be monitored closely during the entire term of treatment in order to detect the development of possible complications. Each patient should be instructed regarding symptoms of deflation, gastrointestinal obstruction, ulceration and other complications which might occur, and should be advised to contact his/her physician immediately upon the onset of such symptoms. Patients need to be evaluated and the device removed at or within 6 months of placement. Clinical data does not exist to support use of an individual orbera? Beyond 6 months. Adverse events: it is important to discuss all possible complications and adverse events with your patient. Complications that may result from the use of this product include the risks associated with the medications and methods utilized in the endoscopic procedure, the risks associated with any endoscopic procedure, the risks associated with the orbera? Intragastric balloon specifically, and the risks associated with the patient's degree of intolerance to a foreign object placed in the stomach. Possible complications - possible complications of the use of orbera? Include: gastric discomfort, feelings of nausea and vomiting following balloon placement as the digestive system adjusts to the presence of the balloon. Continuing nausea and vomiting. This could result from direct irritation of the lining of the stomach, delayed gastric emptying and/or the balloon blocking the outlet of the stomach. It is even theoretically possible that the balloon could prevent vomiting (not nausea or retching) by blocking the inlet to the stomach from the esophagus. Abdominal or back pain; either steady or cyclic.
Patient Sequence No: 1, Text Type: N, H10


[182191149] Reported as: patient presented pain, nausea, vomiting, and aspiration. The patient presented some mucosal hemorrhage during balloon removal. Images confirmed ischemic injury and mucosal necrosis.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3006722112-2020-00018
MDR Report Key9747063
Report SourceCOMPANY REPRESENTATIVE,HEALTH
Date Received2020-02-24
Date of Report2020-01-25
Date of Event2020-01-25
Date Mfgr Received2020-01-25
Device Manufacturer Date2019-05-17
Date Added to Maude2020-02-24
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactDR. DAVID HOOPER
Manufacturer Street1120 S. CAPITAL OF TEXAS HWY BLDG 1, STE. 300
Manufacturer CityCS
Manufacturer CountryUS
Manufacturer G1APOLLO ENDOSURGERY COSTA RICA, SRL
Manufacturer StreetCOYOL FREE ZONE BUILDING B 13.3
Manufacturer CityALAJUELA, CS
Manufacturer CountryCS
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameORBERA? INTRAGASTRIC BALLOON SYSTEM
Generic NameINTRAGASTRIC BALLOON
Product CodeLTI
Date Received2020-02-24
Model NumberB-4800
Catalog NumberB-4800
Lot NumberAF02815
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerAPOLLO ENDOSURGERY, INC.
Manufacturer Address1120 S. CAPITAL OF TEXAS HWY BLDG 1, STE. 300 AUSTIN, TX US


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization; 2. Required No Informationntervention 2020-02-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.